WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS' LIVES, RESEARCHERS PROJECT Sue Decotiis, M.D., a medical weight loss doctor in New York City, agreed that GLP-1s are known to "greatly reduce" systemic inflammation by reducing cytokines, which are inflammatory factors produced by fat cells
( post-hoc analysis on the GLP-1 levels at 0, 30, and 120 min, GLP-1 30 min , GLP1 120 min and AUC GLP-1 in metformin-treated or metformin-naive T2DM patients and noted no significant differences (data not shown)
Implications for neurodegenerative diseases The potential for GLP-1R agonism to protect the brain and improve cognitive function has spurred interest in its use as a therapeutic strategy for neurodegenerative diseases like Alzheimer's
Further rigorous clinical investigation is needed before any conclusions can be drawn about efficacy or safety in IBD populations
New research suggests that people with obesity who take GLP-1 drugs appear to scale back on physical activity once they start taking the drug
Patients should be educated about hypoglycaemia symptoms and the importance of glucose monitoring, particularly during dose titration